NAME OF DRUG : SEMAGLUTIDE
ALSO KNOWN AS : SEMAGLUTIDE
LABORATORY : NOVONORDISK
STATUS AND ADVANCEMENT
Type of drug : GLP_1analog
Clinical trials advancement : Analysing Results Phase 2b
and is eligible for Subpart H on intermediate results of Phase 3
Estimated time to market : 63 months.
LABORATORY ABSTRACT ON THE DRUG
Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose- dependent manner, while decreasing appetite and food intake.3 With SUSTAIN 6, semaglutide, administered subcutaneously once-weekly, has completed six phase 3a clinical trials for the treatment of adults with type 2 diabetes.
RECENT NEWS ON SEMAGLUTIDE
2020-05-06 : Novo Nordisk's diabetes med semaglutide shows promise in NASH. Can it deliver in phase 3?
2019-04-12 : Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
2019-03-20 : Novo Nordisk submits diabetes pill for U.S. approval
2017-08-19 : SEMAGLUTIDE PERSPECTIVES IN NASH
SOME PUBLICATIONS RELATED WITH SEMAGLUTIDE
November 2018 : Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
August 2017 : Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside
July 2017 : Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease